Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Descriptor ID |
D023041
|
MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2005 | 1 | 0 | 1 |
2006 | 0 | 1 | 1 |
2011 | 0 | 2 | 2 |
2013 | 0 | 3 | 3 |
2014 | 0 | 1 | 1 |
2015 | 0 | 1 | 1 |
2016 | 0 | 6 | 6 |
2017 | 2 | 95 | 97 |
2018 | 2 | 90 | 92 |
2019 | 2 | 32 | 34 |
To return to the timeline, click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Molecular PET/CT Profiling of ACE2 Expression In Vivo: Implications for Infection and Outcome from SARS-CoV-2. Adv Sci (Weinh). 2021 08; 8(16):e2100965.
-
Withaferin A: a potential therapeutic agent against COVID-19 infection. J Ovarian Res. 2020 Jul 19; 13(1):79.
-
Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma. Blood Adv. 2019 10 22; 3(20):3020-3032.
-
Genome-wide copy number variation analysis identified ANO1 as a novel oncogene and prognostic biomarker in esophageal squamous cell cancer. Carcinogenesis. 2019 10 16; 40(10):1198-1208.
-
A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma. Cancer Res. 2019 Dec 15; 79(24):6166-6177.
-
Rivaroxaban does not affect growth of human pancreatic tumors in mice. J Thromb Haemost. 2019 12; 17(12):2169-2173.
-
Pembrolizumab in lung cancer: current evidenceĀ and future perspectives. Future Oncol. 2019 Oct; 15(29):3327-3336.
-
Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. Cancer Res. 2019 10 01; 79(19):5060-5073.
-
SDH5 Depletion Enhances Radiosensitivity by Regulating p53: A New Method for Noninvasive Prediction of Radiotherapy Response. Theranostics. 2019; 9(22):6380-6395.
-
Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells. Cancer Sci. 2019 Oct; 110(10):3275-3287.